Provided by Tiger Trade Technology Pte. Ltd.

Inventiva S.A.

3.32
-0.0450-1.34%
Pre-market: 3.27-0.0497-1.50%08:47 EDT
Volume:2.17M
Turnover:7.13M
Market Cap:783.52M
PE:-3.16
High:3.39
Open:3.34
Low:3.16
Close:3.37
52wk High:7.98
52wk Low:3.11
Shares:236.00M
Float Shares:166.00M
Volume Ratio:0.66
T/O Rate:1.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0514
EPS(LYR):-2.2308
ROE:-989.05%
ROA:-42.68%
PB:11.86
PE(LYR):-1.49

Loading ...

Inventiva price target raised to $18 from $13 at Truist

TIPRANKS
·
Oct 02

Truist Raises Price Target on Inventiva to $18 From $13, Keeps Buy Rating

MT Newswires Live
·
Oct 02

Inventiva (IVA) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Sep 30

Inventiva is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Sep 30

Analysts Have Conflicting Sentiments on These Healthcare Companies: Roche Holding AG (OtherRHHVF), Adagene (ADAG) and Inventiva (IVA)

TIPRANKS
·
Sep 29

Inventiva price target raised to $21 from $20 at Canaccord

TIPRANKS
·
Sep 29

Analysts Offer Insights on Healthcare Companies: Inventiva (IVA) and Moderna (MRNA)

TIPRANKS
·
Sep 29

France's Inventiva H1 Net Loss Narrows

Reuters
·
Sep 28

Inventiva H1 EPS $(0.29) Misses $(0.20) Estimate, Sales $23.251K Miss $10.000M Estimate

Benzinga Earnings
·
Sep 28

Inventiva SA Expected to Post a Loss of 49 Cents a Share - Earnings Preview

Reuters
·
Sep 26

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Celldex (CLDX) and Inventiva (IVA)

TIPRANKS
·
Sep 23

Analysts Offer Insights on Healthcare Companies: Surgery Partners (SGRY), Envista Holdings (NVST) and Inventiva (IVA)

TIPRANKS
·
Sep 18

Inventiva Currently Down 10 Consecutive Days, on Pace for Longest Losing Streak

Dow Jones
·
Sep 17

Analysts Have Conflicting Sentiments on These Healthcare Companies: SanBio Co (OtherSNBIF), Immutep Ltd (OtherPRRUF) and Inventiva (IVA)

TIPRANKS
·
Sep 15

Inventiva price target raised to $14 from $11 at Guggenheim

TIPRANKS
·
Sep 15

Guggenheim Sticks to Its Buy Rating for Inventiva (IVA)

TIPRANKS
·
Sep 15

Inventiva Says All Patients Completed 72-Week Treatment Period in Phase 3 Liver Disease Study

MT Newswires Live
·
Sep 03

Inventiva announces last patient visit in NATiV3 trial

TIPRANKS
·
Sep 03

Inventiva Names Chris Benecchi COO

MT Newswires Live
·
Sep 01

Inventiva appoints Chris Benecchi as COO

TIPRANKS
·
Sep 01